Oragenics CEO Kimberly Murphy departs; Pope named Exec Chairman, Redmond Interim PEO

ORAGENICS INC

CEO Kimberly Murphy separated from company Feb 12, 2024, per mutual agreement; remains on board of directors.
Charlie Pope appointed Executive Chairman, Michael Redmond named Interim Principal Executive Officer immediately.
Separation provides benefits under employment agreement for termination without cause; no disagreement cited.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Michael Redmond

Interim Principal Executive Officer

OGEN · ORAGENICS INC

Effective: 2024-02-12
Filed: February 12, 2024, 6:59 PM ET

In addition, effective February 12, 2024, the Board appointed Michael Redmond, the Company’s President, as the Company’s Interim Principal Executive Officer.

Role change (interim)

Charlie Pope

Executive Chairman

OGEN · ORAGENICS INC

Effective: 2024-02-12
Filed: February 12, 2024, 6:59 PM ET

The Board will provide direction to the Company during this transition in management, with Charlie Pope, the Company’s Chairman of the Board, serving, on an interim basis, as Executive Chairman, effective immediately.

Departed

Kimberly Murphy

Chief Executive Officer

OGEN · ORAGENICS INC

Effective: 2024-02-12
Successor: Michael Redmond
Filed: February 12, 2024, 6:59 PM ET

On February 12, 2024, Oragenics, Inc. (the “Company”) and Kimberly Murphy, the Company’s Chief Executive Officer, entered into a mutually agreeable Separation Agreement (the “Separation Agreement”), pursuant to which Ms. Murphy’s employment with the Company terminated effective February 12, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Redmond was appointed as Interim Principal Executive Officer at ORAGENICS INC.

Action: appointed
Role: Interim Principal Executive Officer

Exact text from the filing

In addition, effective February 12, 2024, the Board appointed Michael Redmond, the Company’s President, as the Company’s Interim Principal Executive Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Charlie Pope was appointed as Executive Chairman at ORAGENICS INC.

Action: appointed
Role: Executive Chairman

Exact text from the filing

The Board will provide direction to the Company during this transition in management, with Charlie Pope, the Company’s Chairman of the Board, serving, on an interim basis, as Executive Chairman, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kimberly Murphy was terminated as Chief Executive Officer at ORAGENICS INC.

Action: terminated
Role: Chief Executive Officer

Exact text from the filing

On February 12, 2024, Oragenics, Inc. (the “Company”) and Kimberly Murphy, the Company’s Chief Executive Officer, entered into a mutually agreeable Separation Agreement (the “Separation Agreement”), pursuant to which Ms. Murphy’s employment with the Company terminated effective February 12, 2024.

View on SEC.gov

ORAGENICS INC filing history →

Source: SEC EDGAR

accession 0001493152-24-005916

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.